UP!

BOTA $1.55   View long term graphs

Biota was an Australian antiviral drug development company listed on the Australian Stock Exchange (ASX:BTA).

In 1989 Biota discovered the drug Zanamivir, which acts as a neuraminidase inhibitor for the treatment and prevention of influenza. This drug is licensed to GlaxoSmithKline and marketed as Relenza.

In November 2012, Biota Holdings Limited merged with American company Nabi Biopharmaceuticals to form Biota Pharmaceuticals.

The combined company has its headquarters in the U.S. and is now listed on the NASDAQ under the abbreviated code BOTA.


Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2016 2016-09-19 Future report Set alerts
Q3 2016 2016-05-05 Future report Set alerts
Q2 2016 2016-02-05 -0.17 -0.17
Q1 2016 2015-11-06 0.00 -0.17
Q4 2015 2015-09-11 0.00 -0.55
Q3 2015 2015-05-07 0.00 0.03
Q2 2015 2015-02-05 0.19 0.19
Q1 2015 2014-11-07 -0.20 -0.20
Q4 2014 2014-09-26 -0.29 -0.29
Q3 2014 2014-05-06 0.09 0.09

Ratings

2016-03-18 Reiterated Rating FBR & Co. Buy
2016-02-08 Reiterated Rating FBR & Co. Outperform $6.00
2016-01-27 Reiterated Rating FBR & Co. Outperform $6.00
2016-01-27 Initiated Coverage HSBC Buy
2016-01-26 Initiated Coverage FBR & Co. Buy
2015-12-28 Initiated Coverage FBR & Co. Buy
2015-12-22 Initiated Coverage FBR & Co. Outperform $6.00
2014-08-04 Downgrade Guggenheim Buy to Neutral $5.00 to $3.00
1970-01-01
2016-03-18 Reiterated Rating FBR & Co. Buy
2016-02-08 Reiterated Rating FBR & Co. Outperform $6.00
2016-01-27 Reiterated Rating FBR & Co. Outperform $6.00
2016-01-27 Initiated Coverage HSBC Buy
2016-01-26 Initiated Coverage FBR & Co. Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In BOTA 1 funds of 2183 total. Show all

Fund name Ticker shares
Dominick & Dominick LLC 0.15M

Major Shareholders

Name Relationship Total Shares Holding stocks

Comments